The closing price of Vir Biotechnology Inc (NASDAQ: VIR) was $10.00 for the day, down -6.37% from the previous closing price of $10.68. In other words, the price has decreased by -$0.68 from its previous closing price. On the day, 1347729 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of VIR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.05 and its Current Ratio is at 9.05. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $23 previously.
On September 08, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $23 to $14.
JP Morgan Upgraded its Neutral to Overweight on March 06, 2023, whereas the target price for the stock was revised from $35 to $34.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 26 ’24 when SCANGOS GEORGE A sold 17,722 shares for $11.65 per share. The transaction valued at 206,522 led to the insider holds 112,989 shares of the business.
Pang Phillip sold 14,568 shares of VIR for $146,344 on Feb 22 ’24. The EVP & Chief Medical Officer now owns 250,111 shares after completing the transaction at $10.05 per share. On Feb 22 ’24, another insider, HANLY ANN M., who serves as the EVP & Chief Technology Officer of the company, sold 12,296 shares for $10.05 each. As a result, the insider received 123,521 and left with 134,780 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 1.44B and an Enterprise Value of 44.28M. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.67 while its Price-to-Book (P/B) ratio in mrq is 0.85. Its current Enterprise Value per Revenue stands at 1.12 whereas that against EBITDA is -0.07.
Stock Price History:
Over the past 52 weeks, VIR has reached a high of $27.48, while it has fallen to a 52-week low of $7.72. The 50-Day Moving Average of the stock is 10.20, while the 200-Day Moving Average is calculated to be 12.68.
Shares Statistics:
VIR traded an average of 1.12M shares per day over the past three months and 1.05M shares per day over the past ten days. A total of 134.78M shares are outstanding, with a floating share count of 87.99M. Insiders hold about 34.83% of the company’s shares, while institutions hold 53.39% stake in the company. Shares short for VIR as of Feb 29, 2024 were 5.08M with a Short Ratio of 4.54, compared to 5.77M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.76% and a Short% of Float of 6.32%.
Earnings Estimates
The firm’s stock currently is rated by 7 analysts. On average, analysts expect EPS of -$1.05 for the current quarter, with a high estimate of -$0.79 and a low estimate of -$1.32, while EPS last year was -$1.06. The consensus estimate for the next quarter is -$1.03, with high estimates of -$0.91 and low estimates of -$1.23.
Analysts are recommending an EPS of between -$3.43 and -$4.94 for the fiscal current year, implying an average EPS of -$4.09. EPS for the following year is -$3.98, with 9 analysts recommending between -$2.83 and -$5.66.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $39.4M to a low estimate of $4.26M. As of the current estimate, Vir Biotechnology Inc’s year-ago sales were $50.1M, an estimated decrease of -76.10% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $9.35M, an increase of 146.20% over than the figure of -$76.10% in the same quarter last year. There is a high estimate of $21.3M for the next quarter, whereas the lowest estimate is $6M.
A total of 8 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $121.8M, while the lowest revenue estimate was $22.69M, resulting in an average revenue estimate of $41.37M. In the same quarter a year ago, actual revenue was $86.18M, down -52.00% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $41.61M in the next fiscal year. The high estimate is $106.2M and the low estimate is $17.69M. The average revenue growth estimate for next year is up 0.60% from the average revenue estimate for this year.
